Abstract
Myostatin is a negative regulator of muscle mass. Important advances in our understanding of thecomplex biology of this factor have revealed the therapeutic potential of antagonizing the myostatin pathway. Herewe present the rationale for evaluating anti-myostatin therapies in human muscle-wasting disorders.
Keywords: Myostatin, Muscle, Adipose tissue, Rhabdomyosarcoma, Myostatin antagonism, Myostatin processing and signaling, therapeutic approaches
Mini-Reviews in Medicinal Chemistry
Title: Myostatin: Biology and Clinical Relevance
Volume: 6 Issue: 7
Author(s): Gilles Carnac, Stephanie Ricaud, Barbara Vernus and Anne Bonnieu
Affiliation:
Keywords: Myostatin, Muscle, Adipose tissue, Rhabdomyosarcoma, Myostatin antagonism, Myostatin processing and signaling, therapeutic approaches
Abstract: Myostatin is a negative regulator of muscle mass. Important advances in our understanding of thecomplex biology of this factor have revealed the therapeutic potential of antagonizing the myostatin pathway. Herewe present the rationale for evaluating anti-myostatin therapies in human muscle-wasting disorders.
Export Options
About this article
Cite this article as:
Carnac Gilles, Ricaud Stephanie, Vernus Barbara and Bonnieu Anne, Myostatin: Biology and Clinical Relevance, Mini-Reviews in Medicinal Chemistry 2006; 6 (7) . https://dx.doi.org/10.2174/138955706777698642
DOI https://dx.doi.org/10.2174/138955706777698642 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Heterocyclic Scaffolds: Centrality in Anticancer Drug Development
Current Drug Targets Zebrafish: A Complete Animal Model for In Vivo Drug Discovery and Development
Current Drug Metabolism The ALK Gene, An Attractive Target for Inhibitor Development
Current Topics in Medicinal Chemistry Management of Glioblastoma Multiforme by Phytochemicals: Applications of Nanoparticle-Based Targeted Drug Delivery System
Current Drug Targets Cryopreservation of Ovarian Tissue: State of the Art in 2007
Current Women`s Health Reviews Clinical Considerations of Focal Drug Delivery in Cancer Treatment
Current Drug Delivery Peptidyl Prolyl Isomerase, Pin1 is a Potential Target for Enhancing the Therapeutic Efficacy of Etoposide
Current Cancer Drug Targets Anticancer Properties of Flavonoids: Roles in Various Stages of Carcinogenesis
Cardiovascular & Hematological Agents in Medicinal Chemistry Genetic Predisposition to Neonatal Tumors
Current Pediatric Reviews Retinoids as Differentiating Agents in Oncology: A Network of Interactions with Intracellular Pathways as the Basis for Rational Therapeutic Combinations
Current Pharmaceutical Design Differentiation-Inducing Therapy for Solid Tumors
Current Pharmaceutical Design Tumor Biomarkers: Clinical Utility, Promises and Problems
Applied Clinical Research, Clinical Trials and Regulatory Affairs Adiponectin: Merely a Bystander or the Missing Link to Cardiovascular Disease?
Current Topics in Medicinal Chemistry From French Paradox to Cancer Treatment: Anti-cancer Activities and Mechanisms of Resveratrol
Anti-Cancer Agents in Medicinal Chemistry Cyclodepsipeptides - Potential Drugs and Lead Compounds in the Drug Development Process
Current Medicinal Chemistry Targeting the Atypical Chemokine Receptor ACKR3/CXCR7: Phase 1 - Phage Display Peptide Identification and Characterization
Current Topics in Medicinal Chemistry Analysis of the Potential for HIV-1 Vpr as an Anti-Cancer Agent
Current HIV Research Targeting Receptor Tyrosine Kinases Using Monoclonal Antibodies: The Most Specific Tools for Targeted-Based Cancer Therapy
Current Drug Targets Perinatal Management of Fetal Tumors
Current Pediatric Reviews Statin-Induced Myotoxicity: Pharmacokinetic Differences among Statins and the Risk of Rhabdomyolysis, with Particular Reference to Pitavastatin
Current Vascular Pharmacology